BRPI1014027A2 - suspensão de fármaco de nanopartícula estável. - Google Patents
suspensão de fármaco de nanopartícula estável.Info
- Publication number
- BRPI1014027A2 BRPI1014027A2 BRPI1014027A BRPI1014027A BRPI1014027A2 BR PI1014027 A2 BRPI1014027 A2 BR PI1014027A2 BR PI1014027 A BRPI1014027 A BR PI1014027A BR PI1014027 A BRPI1014027 A BR PI1014027A BR PI1014027 A2 BRPI1014027 A2 BR PI1014027A2
- Authority
- BR
- Brazil
- Prior art keywords
- drug suspension
- nanoparticle drug
- stable nanoparticle
- stable
- suspension
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21828109P | 2009-06-18 | 2009-06-18 | |
| PCT/US2010/038526 WO2010147899A1 (en) | 2009-06-18 | 2010-06-14 | Stable nanoparticulate drug suspension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1014027A2 true BRPI1014027A2 (pt) | 2019-09-24 |
Family
ID=42797219
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1014027A BRPI1014027A2 (pt) | 2009-06-18 | 2010-06-14 | suspensão de fármaco de nanopartícula estável. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100323020A1 (pt) |
| EP (1) | EP2442789A1 (pt) |
| JP (1) | JP2012530704A (pt) |
| KR (1) | KR20120052937A (pt) |
| CN (1) | CN102802609A (pt) |
| AU (1) | AU2010260226A1 (pt) |
| BR (1) | BRPI1014027A2 (pt) |
| CA (1) | CA2764187A1 (pt) |
| IL (1) | IL216593A0 (pt) |
| MX (1) | MX2011013797A (pt) |
| RU (1) | RU2012101627A (pt) |
| SG (1) | SG176929A1 (pt) |
| TW (1) | TW201103573A (pt) |
| WO (1) | WO2010147899A1 (pt) |
| ZA (1) | ZA201109219B (pt) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8362013B2 (en) * | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
| US8728516B2 (en) * | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| US20100280031A1 (en) * | 2009-04-30 | 2010-11-04 | Paul David | Lipid formulation of apoptosis promoter |
| TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
| TWI471321B (zh) * | 2009-06-08 | 2015-02-01 | 亞培公司 | Ｂｃｌ－２族群抑制劑之口服醫藥劑型 |
| US8927009B2 (en) * | 2009-12-22 | 2015-01-06 | Abbvie Inc. | ABT-263 capsule |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| US8716363B2 (en) | 2011-09-28 | 2014-05-06 | Globus Medical, Inc. | Biodegradable putty compositions and implant devices, methods, and kits relating to the same |
| EP2763668A4 (en) * | 2011-10-05 | 2015-04-15 | Douglas Pharmaceuticals Ltd | PHARMACEUTICAL PROCESSES AND TOPICAL COMPOSITIONS WITH ACITRETIN |
| CN105050585A (zh) * | 2013-03-04 | 2015-11-11 | Vtv治疗有限责任公司 | 稳定的葡萄糖激酶活化剂组合物 |
| ES2670995T3 (es) | 2013-03-12 | 2018-06-04 | Cephalon, Inc. | Formulaciones de nanopartículas y macropartículas |
| US10556916B2 (en) * | 2014-04-01 | 2020-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Zirconium-89 oxine complex as a cell labeling agent for positron emission tomography |
| KR20170008252A (ko) * | 2014-05-09 | 2017-01-23 | 아우로메딕스 파마 엘엘씨 | 사이클로포스파미드 액상 농축 제제 |
| WO2016105499A1 (en) | 2014-12-23 | 2016-06-30 | Intellectual Property Associates, Llc | Methods and formulations for transdermal administration |
| IL285928B2 (en) | 2016-05-06 | 2025-06-01 | Eagle Pharmaceuticals Inc | Fulvestrant formulations and methods of their use |
| US11207307B2 (en) | 2016-06-16 | 2021-12-28 | Azurity Pharmaceuticals, Inc. | Composition and method for proton pump inhibitor suspension |
| US20200031920A1 (en) * | 2017-04-04 | 2020-01-30 | The George Washington University | Combination Therapy for Treating Cancer |
| EP3681479B1 (en) | 2017-09-15 | 2024-01-31 | Dyve Biosciences, Inc. | Sodium bicarbonate for use in the treatment of gout and related disorders |
| KR20200108301A (ko) | 2018-01-10 | 2020-09-17 | 리커리엄 아이피 홀딩스, 엘엘씨 | 벤즈아미드 화합물 |
| EP3826675A1 (en) * | 2018-07-24 | 2021-06-02 | January Therapeutics, Inc. | Nanoparticle compositions |
| US10751333B1 (en) | 2019-07-16 | 2020-08-25 | Cutispharma, Inc. | Compositions and kits for omeprazole suspension |
| US11633478B2 (en) | 2019-07-16 | 2023-04-25 | Azurity Pharmaceuticals, Inc. | Compositions and kits for Omeprazole suspension |
| KR20220098755A (ko) | 2019-11-05 | 2022-07-12 | 애브비 인코포레이티드 | 나비토클락스를 사용한 골수섬유증 및 mpn 관련 장애 치료에 사용하기 위한 투약 레지멘 |
| US20210169903A1 (en) * | 2019-12-09 | 2021-06-10 | Tyme, Inc. | Pharmaceutical compositions and methods |
| CN117599041B (zh) * | 2024-01-22 | 2024-05-03 | 中国人民解放军军事科学院军事医学研究院 | 去氢雌马酚及其衍生物作为新型辐射防护剂和细胞保护剂的医药用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1471887B1 (en) | 2002-02-04 | 2010-04-21 | Elan Pharma International Ltd. | Nanoparticulate compositions having lysozyme as a surface stabilizer |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| PL1888550T3 (pl) * | 2005-05-12 | 2014-12-31 | Abbvie Bahamas Ltd | Promotory apoptozy |
| JP5277168B2 (ja) * | 2006-09-05 | 2013-08-28 | アボット・ラボラトリーズ | 血小板過剰を治療するｂｃｌインヒビター |
| EP2219651A1 (en) * | 2007-12-06 | 2010-08-25 | Abbott Laboratories | Oral compositions of abt-263 for treating cancer |
-
2010
- 2010-06-14 KR KR1020127001358A patent/KR20120052937A/ko not_active Withdrawn
- 2010-06-14 WO PCT/US2010/038526 patent/WO2010147899A1/en not_active Ceased
- 2010-06-14 CN CN2010800368047A patent/CN102802609A/zh active Pending
- 2010-06-14 JP JP2012516170A patent/JP2012530704A/ja not_active Withdrawn
- 2010-06-14 AU AU2010260226A patent/AU2010260226A1/en not_active Abandoned
- 2010-06-14 MX MX2011013797A patent/MX2011013797A/es not_active Application Discontinuation
- 2010-06-14 RU RU2012101627/15A patent/RU2012101627A/ru unknown
- 2010-06-14 EP EP10724981A patent/EP2442789A1/en not_active Withdrawn
- 2010-06-14 CA CA2764187A patent/CA2764187A1/en not_active Abandoned
- 2010-06-14 SG SG2011094406A patent/SG176929A1/en unknown
- 2010-06-14 BR BRPI1014027A patent/BRPI1014027A2/pt not_active IP Right Cessation
- 2010-06-17 US US12/817,640 patent/US20100323020A1/en not_active Abandoned
- 2010-06-18 TW TW099119972A patent/TW201103573A/zh unknown
-
2011
- 2011-11-24 IL IL216593A patent/IL216593A0/en unknown
- 2011-12-14 ZA ZA2011/09219A patent/ZA201109219B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120052937A (ko) | 2012-05-24 |
| AU2010260226A1 (en) | 2012-02-02 |
| SG176929A1 (en) | 2012-01-30 |
| WO2010147899A1 (en) | 2010-12-23 |
| CN102802609A (zh) | 2012-11-28 |
| TW201103573A (en) | 2011-02-01 |
| US20100323020A1 (en) | 2010-12-23 |
| CA2764187A1 (en) | 2010-12-23 |
| EP2442789A1 (en) | 2012-04-25 |
| IL216593A0 (en) | 2012-02-29 |
| ZA201109219B (en) | 2013-05-29 |
| JP2012530704A (ja) | 2012-12-06 |
| MX2011013797A (es) | 2012-01-30 |
| RU2012101627A (ru) | 2013-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1014027A2 (pt) | suspensão de fármaco de nanopartícula estável. | |
| HUS2300018I1 (hu) | Rákellenes hatású kinoli-8-szulfonamid-származékok | |
| BRPI0906611A2 (pt) | Produtos implantáveis compreendendo nanopartículas. | |
| HRP20170959T1 (hr) | Farmaceutska suspenzija | |
| BRPI0920514A2 (pt) | infusão de fármacos | |
| BR112012008156A2 (pt) | conjunto de cateter com abertura reselável | |
| BR112012011902A2 (pt) | cápsula farmacêutica | |
| EP2646818A4 (en) | SILICANANOPARTIKELKONJUGATE | |
| BRPI1016117A2 (pt) | derivados de isoxazol-isoxazol e isoxasol-isotiazol. | |
| BRPI1013235A2 (pt) | suspensão de veículo | |
| BRPI1008899A2 (pt) | derivados 3,3´-espiroindolinona como agentes anticâncer | |
| UY33125A (es) | Diaza-espiro-[5,5]-undecanos | |
| BRPI1016190A2 (pt) | compostos farmacêuticos. | |
| PL3005986T3 (pl) | Infuzja leków | |
| EP2292752A4 (en) | CAPSULE WITHOUT SOLDER | |
| BRPI1014388A2 (pt) | preparação de sólido. | |
| IT1396487B1 (it) | Convogliatore. | |
| DK2437736T3 (da) | Lægemiddelindgivelsessystemer | |
| DK2506831T3 (da) | Carboxyvinylpolymerholdige nanopartikelsuspensioner | |
| DK2442870T3 (da) | Pyrazinooxazepin-derivater. | |
| BRPI1016192A2 (pt) | derivados de soxazol. | |
| BRPI1014897A8 (pt) | dispositivo de suspensão. | |
| BR112012000654A2 (pt) | estruturas de suspensao | |
| BRPI1016203A2 (pt) | diferencial | |
| BR112012001680A2 (pt) | Derivados de tazaroteno |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |